Wondering what is the difference between semaglutide and tirzepatide compound? Compare how these two GLP-1 drugs work, their doses, results, and FDA status.
The main difference between semaglutide and tirzepatide is the number of hormone receptors each drug activates. Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP and GLP-1 receptor agonist. Compounded versions of both are custom-made by compounding pharmacies, are not FDA-approved, and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
One Receptor vs. Two: The Core Difference
Semaglutide mimics a gut hormone called GLP-1. It slows stomach emptying, boosts feelings of fullness, and reduces appetite. Tirzepatide does all of that and also activates GIP, a second incretin hormone involved in insulin release and fat metabolism.
That extra target is why tirzepatide tends to produce greater average weight loss in trials. Head-to-head studies are limited, so most comparisons rely on separate trials rather than direct competition between the two drugs.
When people search for the tirzepatide and semaglutide difference, they are usually trying to answer three practical questions: how the drugs work, how much weight people lose, and what they cost.
Semaglutide vs. Tirzepatide: Side-by-Side Comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| FDA-approved brands | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Approved uses | Type 2 diabetes, chronic weight management, cardiovascular risk reduction | Type 2 diabetes, chronic weight management, obstructive sleep apnea |
| Typical weekly dose | 0.25 mg titrated up to 2.4 mg (Wegovy) | 2.5 mg titrated up to 15 mg |
| Average weight loss in trials | About 15% of body weight over 68 weeks (STEP-1) | About 21% of body weight over 72 weeks (SURMOUNT-1) |
| Available forms | Weekly injection; daily oral tablet for diabetes | Weekly injection |
| Compounded version | Not FDA-approved; shortage declared resolved in 2025 | Not FDA-approved; shortage declared resolved in 2024 |
Trial percentages come from separate studies with different designs and populations, so they are not a direct prediction of what any one person will experience.
How Compounded Versions Differ From the Brand-Name Drugs
Compounded semaglutide and compounded tirzepatide are custom preparations made by licensed compounding pharmacies. They are not reviewed by the FDA for safety, effectiveness, or purity, and they are not generic equivalents of the brand-name products.
Practical differences worth knowing about:
- Different drug forms. Some compounded products have used salt forms such as semaglutide sodium, which are not the same molecule as the approved drug.
- Variable strength. Concentrations can differ between pharmacies and even between refills from the same pharmacy.
- Unfamiliar units. Many compounded vials are dosed in "units" on a syringe rather than milligrams, which makes dosing errors more likely.
- Shifting availability. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then directed compounders to stop producing copies. Legal challenges have continued since.
Regulators have logged reports of dosing errors and adverse events tied to compounded GLP-1 products, including cases where patients took far more drug than intended.
Dosing, Cost, and What You Are Actually Buying
Cost is the main reason people explore compounded options. Brand-name GLP-1 medications can exceed $1,000 per month without insurance, while compounded vials have often sold for a few hundred dollars a month.
The titration pattern is broadly similar for both drugs: start low and increase roughly every four weeks to limit gastrointestinal side effects. Compounded products do not always follow an approved titration schedule, and some sellers offer strengths that match no FDA-approved dose.
Gray-market vials sold as "research chemicals" are a different category entirely. They often arrive as a powder that must be mixed before use, which leads people to search for what is the best bac water for peptides. An unlabeled vial from an unverified seller is a poor foundation for any dosing decision.
Side Effects and Safety
Semaglutide and tirzepatide share a similar side-effect profile because both act on GLP-1 receptors. Common effects include nausea, vomiting, diarrhea, constipation, burping, fatigue, and injection-site reactions.
More serious risks include pancreatitis, gallbladder disease, gastroparesis, severe dehydration, and loss of lean muscle mass. Both drug classes carry a boxed warning about thyroid C-cell tumors observed in rodents and are contraindicated in people with a personal or family history of medullary thyroid cancer or MEN2.
Can You Take Semaglutide and Tirzepatide at the Same Time?
No. The question can you take semaglutide and tirzepatide at the same time has a clear answer: combining two GLP-1-based drugs is not supported by clinical evidence and stacks identical side effects on top of each other. Anyone who wants to switch from one to the other should do so under a prescriber's supervision, usually restarting at a low dose.
Before starting either drug, discuss what is semaglutide used for in your specific situation with a licensed healthcare professional, and review every other medication and supplement you take.
Where Retatrutide and Other Peptides Fit In
The search for what is the retatrutide peptide reflects growing interest in the next generation of weight-loss drugs. Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors. It is not FDA-approved for any use and is currently available only through clinical trials.
Peptide research is easy to confuse with prescription medicine. GLP-1 drugs such as semaglutide and tirzepatide are FDA-regulated prescription products, not laboratory research peptides, and they should be treated that way.
Frequently Asked Questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is not FDA-approved and is not a generic version of Ozempic or Wegovy. It may contain a different form of the active ingredient, a different strength, or impurities, and the FDA has not reviewed it for safety, effectiveness, or manufacturing quality.
Which works better for weight loss, semaglutide or tirzepatide?
In separate clinical trials, tirzepatide produced greater average weight loss than semaglutide: about 21% of body weight over 72 weeks in SURMOUNT-1 versus about 15% over 68 weeks in STEP-1. These were not head-to-head studies, and individual results vary widely. Compounded versions have not been tested in comparable trials at all.
Can I switch from semaglutide to tirzepatide?
Yes, switching is possible, but only under a prescriber's supervision. Most clinicians restart at the lowest dose of the new medication and titrate up again to limit gastrointestinal side effects. Do not combine the two drugs or use leftover doses of both.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.